PT Lippo Karawaci Tbk (LPKR) Fair Value & Analysis
Healthcare · ID · Market cap 4.4T IDR
Fair value as of: Jul 19, 2026
From 7 valuation models · updated 22 days ago
Share price +10.0% over the past month.
Below-average quality, screening 45% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (26/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (71.79 IDR). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range 52.00 IDR – 220.00 IDR · fair‑value band 71.79 IDR – 119.65 IDR · the 66.00 IDR price screens below the 95.73 IDR fair value. Dashed = 300-day average. As of Jul 19, 2026.
Analysis
PT Lippo Karawaci Tbk (LPKR) currently trades at 66.00 IDR, while our model-based Fair Value estimate is 95.73 IDR, implying the stock looks roughly 45.0% undervalued today. The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PT Lippo Karawaci Tbk generated revenue of 8.6T IDR at a net margin of 4.7%. Revenue declined 12.7% year over year. It earns a return on equity of 1.5%. Net debt stands at 7.7T IDR. Fundamentals as of Jul 19, 2026
Our scenario range runs from 71.79 IDR (bear case) to 119.65 IDR (bull case); at 66.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 45%, LPKR screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Asset-Based (284.80 IDR) versus Multiples (112.62 IDR). Highest evidence: Residual Income (76).
Notify me when LPKR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 28 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Lippo Karawaci Tbk engages in real estate development, healthcare and lifestyle businesses in Indonesia. The company is also involved in investment, development, trading, home care, and financing activities; installation and water treatment; town management; urban development; marketing and building management; clean water and waste management; hotel …
Full company description
PT Lippo Karawaci Tbk engages in real estate development, healthcare and lifestyle businesses in Indonesia. The company is also involved in investment, development, trading, home care, and financing activities; installation and water treatment; town management; urban development; marketing and building management; clean water and waste management; hotel management; catering service; and provision of accommodation and burial services. PT Lippo Karawaci Tbk founded in 1990 and is based in Tangerang, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Lippo Karawaci Tbk reported revenue of 8.8T IDR in FY2025 versus 16.1T IDR in FY2021, a compound −14.0%/yr. Reported net income was 470B IDR in FY2025.
of which total revenue +2.1 pp · buybacks/dilution −6.9 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch LPKR: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Lippo Karawaci Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Lippo Karawaci Tbk (LPKR) overvalued or undervalued?
What is the fair value of LPKR?
What is the quality score of LPKR?
What is the revenue of PT Lippo Karawaci Tbk (LPKR)?
What is the net profit margin of LPKR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Lippo Karawaci Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.